It's Friday, which means we're back with more Baby Breakers. Over the past week, we partied like it's 1999, spent money to make technology friendlier, and found yet another potential competitor for Rule Breaker Universe member TiVo (Nasdaq: TIVO ) . (You can view all 250 companies in our Universe with a 30-day free trial to Motley Fool Rule Breakers.)
Let's kick things off with Baidu (Nasdaq: BIDU ) , the so-called Google (Nasdaq: GOOG ) of China. You know this story, don't you? I'll leave the details to Foolish colleague Tom Taulli, who covered the debut here. It's enough to say that the stock rose 354% on its first day of trading. Did you think dot-com hysteria was a thing of the past? Silly Fool.
Wednesday brought news from VentureWire of funding for Silicon Valley-based Centrify and New York-based OpTier. Centrify, which centralizes the administration of technology infrastructure, received $14 million in second-round (or "B") financing from Invesco Private Capital, Accel Partners, and Mayfield, which has also been an investor in The Motley Fool. OpTier, which maps networks to pinpoint performance issues, added $9.5 million to bring its B round to $17 million.
Also on Wednesday, VeohNetworks announced it had completed its first round of funding, although it didn't say for how much. Still, the vision is interesting. Veoh plans to use peer-to-peer technology -- think of the old Napster, for example -- to make any kind of video available to your PC. The company's ultimate aim appears to be to create a media server that connects to your TV and allows you to replay what you download. If that sounds eerily like what TiVo had planned in its team-up with Netflix (Nasdaq: NFLX ) , you're not far off.
Finally, thanks to your feedback on our private discussion boards, we roll out a new feature: the week in Baby Breaker public offerings. Here's our short list of the most interesting:
- Coley Pharmaceutical Group (Nasdaq: COLY ) debuted Wednesday at $16 a share and has since risen 14% to $18.25 per stub. Coley is working on several drugs for treating different types of cancer. One drug, CPG 7909, has shown promise in combating non-small-cell lung cancer in trials.
- China Medical Technologies (Nasdaq: CMED ) also went public Wednesday at $15.00 per share. Its devices use ultrasonic waves to treat cancer.
- Finally, shares of steakhouse Ruth's Chris (Nasdaq: RUTH ) were priced at $18, debuted at $19.80, and have since risen to $21.03. Not bad for a one-week return, eh? Yeah, I know, it's not a Breaker. It's just too juicy not to mention. Mmmmm, steak.
See you back here next week.
More Rule Breaking Foolishness:
- David Gardner outlines the six steps to Rule Breaking.
- Alyce Lomax examines a few stocks for the next generation.
Fool contributor Tim Beyers isn't too old to party like it's 1999. Yet. Tim didn't own shares in any of the companies mentioned in this story at the time of publication. You can find out what's in his portfolio by checking Tim's Fool profile. TiVo and Netflix are Motley Fool Stock Advisor recommendations. The Motley Fool has an ironclad disclosure policy.